Don R Cherek1, Oleg V Tcheremissine, Scott D Lane, Cynthia J Pietras. 1. Department of Psychiatry and Behavioral Science, Human Psychopharmacology Laboratory, University of Texas-Houston Health Science Center, 1300 Moursund Street, Houston, TX 77030-3497, USA. don.r.cherek@uth.tmc.edu
Abstract
RATIONALE: The possible role of GABA in human aggression was evaluated by administering gabapentin to subjects with and without a history of conduct disorder and comparing the effects on laboratory measures of aggression and escape. METHODS: Eighteen male and two female subjects with a history of criminal behavior participated in experimental sessions, which measured aggressive and escape responses. Ten subjects had a history of childhood conduct disorder (CD+) and ten subjects with no history (non-CD controls). Aggression was measured using the Point Subtraction Aggression Paradigm (PSAP), which provided subjects aggressive, escape and monetary reinforced response options. RESULTS: Acute doses (200, 400 and 800 mg) of gabapentin had similar effects on aggressive responses among CD+ subjects compared to non-CD control subjects. Aggressive responses of CD+ and non-CD control subjects increased at lower gabapentin doses, and decreased at the highest 800 mg gabapentin dose. Gabapentin increased escape responses for both CD+ and non-CD controls CD- subjects at the lowest dose, but then produced dose-related decreases at the two higher doses in both groups. No changes in monetary reinforced responses were observed, indicative of no CNS stimulation or sedation. CONCLUSIONS: Gabapentin produced similar bitonic effects upon aggressive and escape responses in subjects with and without a history of childhood conduct disorder. This is in marked contrast to prior differential effects of baclofen on aggressive responses between CD+ and non-CD control subjects in a previous study.
RATIONALE: The possible role of GABA in humanaggression was evaluated by administering gabapentin to subjects with and without a history of conduct disorder and comparing the effects on laboratory measures of aggression and escape. METHODS: Eighteen male and two female subjects with a history of criminal behavior participated in experimental sessions, which measured aggressive and escape responses. Ten subjects had a history of childhood conduct disorder (CD+) and ten subjects with no history (non-CD controls). Aggression was measured using the Point Subtraction Aggression Paradigm (PSAP), which provided subjects aggressive, escape and monetary reinforced response options. RESULTS: Acute doses (200, 400 and 800 mg) of gabapentin had similar effects on aggressive responses among CD+ subjects compared to non-CD control subjects. Aggressive responses of CD+ and non-CD control subjects increased at lower gabapentin doses, and decreased at the highest 800 mg gabapentin dose. Gabapentin increased escape responses for both CD+ and non-CD controls CD- subjects at the lowest dose, but then produced dose-related decreases at the two higher doses in both groups. No changes in monetary reinforced responses were observed, indicative of no CNS stimulation or sedation. CONCLUSIONS:Gabapentin produced similar bitonic effects upon aggressive and escape responses in subjects with and without a history of childhood conduct disorder. This is in marked contrast to prior differential effects of baclofen on aggressive responses between CD+ and non-CD control subjects in a previous study.
Authors: Don R Cherek; Scott D Lane; Cynthia J Pietras; Jennifer Sharon; Joel L Steinberg Journal: Psychopharmacology (Berl) Date: 2002-09-03 Impact factor: 4.530
Authors: F de-Paris; J V Busnello; M R Vianna; J B Salgueiro; J Quevedo; I Izquierdo; F Kapczinski Journal: Behav Pharmacol Date: 2000-04 Impact factor: 2.293
Authors: L Singh; M J Field; P Ferris; J C Hunter; R J Oles; R G Williams; G N Woodruff Journal: Psychopharmacology (Berl) Date: 1996-09 Impact factor: 4.530
Authors: Joshua L Gowin; Charles E Green; Joseph L Alcorn; Alan C Swann; F Gerard Moeller; Scott D Lane Journal: J Psychopharmacol Date: 2011-07-05 Impact factor: 4.153
Authors: Scott D Lane; Joshua L Gowin; Charles E Green; Joel L Steinberg; F Gerard Moeller; Don R Cherek Journal: Pharmacol Biochem Behav Date: 2009-04 Impact factor: 3.533
Authors: Matthew S Stanford; Nathaniel E Anderson; Sarah L Lake; Robyn M Baldridge Journal: Curr Treat Options Neurol Date: 2009-09 Impact factor: 3.598